<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="185408">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00680225</url>
  </required_header>
  <id_info>
    <org_study_id>FVF4290s</org_study_id>
    <nct_id>NCT00680225</nct_id>
    <nct_alias>NCT00541528</nct_alias>
  </id_info>
  <brief_title>Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma</brief_title>
  <official_title>Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Retina Associates</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New England Retina Associates</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To report preliminary results on safety and tolerability of intravitreal injection of
      Ranibizumab (Lucentis) combined with Transpupillary Thermotherapy (TTT)+ Indocyanine Green
      (ICG)-based photodynamic therapy (PDT) in the treatment of choroidal melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in tumor size</measure>
    <time_frame>3 mo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity changes</measure>
    <time_frame>3 mo</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Choroidal Melanoma</condition>
  <arm_group>
    <arm_group_label>Lucentis Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab injection and TTT - ICG based</intervention_name>
    <description>Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.</description>
    <arm_group_label>Lucentis Injection</arm_group_label>
    <other_name>Lucentis injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 yo.

          -  Primary pigmented or amelanotic choroidal melanoma measurement of 16 mm or less in
             the largest vessel diameter and 6 mm or less in the apical height.

          -  Location of the tumor posterior to the equator.

          -  Documented growth by A/B scan.

          -  Risk factor for metastasis (thickness greater than 2 mm, symptoms, tumor margin at
             the optic disc)

          -  Ability to provide inform consent.

          -  Comply with the study assessment for the cooperation of the study.

        Exclusion Criteria:

          -  Pregnancy or lactation.

          -  Premenopausal women not using adequate contraception; surgical sterilization or use
             of oral contraception, barrier contraception with either a condom or diaphragm or in
             conjunction with spermicidal gel, an IUD or contraceptive hormon implant or patch.

          -  Current infection or inflammation in either eye.

          -  Extension of tumor into the orbit.

          -  Retinal spread or metastatic disease.

          -  Any other condition that the investigator believes would pose a significant hazard to
             the subject if the investigational therapy were initiated.

          -  Any known allergy to any of the components to be used in the study.

          -  Participation in another simultaneous medical investigation or trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>New England Retina Associates</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 1, 2013</lastchanged_date>
  <firstreceived_date>May 15, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New England Retina Associates</investigator_affiliation>
    <investigator_full_name>Peter E. Liggett</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Choroidal melanoma</keyword>
  <keyword>Lucentis</keyword>
  <keyword>TTT-ICG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
